ReviewCancer cell international2026
The emerging role of TROP2 as a diagnostic and prognostic biomarker in bladder tumor.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.Frontiers in medicine · 2026Review
- TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome.Frontiers in oncology · 2026Article
- TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer, predominantly urothelial carcinoma (UC), remains a significant global health challenge due to high recurrence rates and treatment resistance. While standard diagnostic methods such as urinary cytology and cystoscopy are widely used, they have limited sensitivity and specificity. Recently, Trophoblast Cell Surface Antigen 2 (TROP2) has emerged as a promising biomarker and therapeutic target in UC. Highly expressed in urothelial tumors but minimally present in normal tissues, TROP2 plays a crucial role in tumor proliferation, adhesion, and invasion. Immunohistochemical and molecular studies have demonstrated its potential diagnostic and prognostic value, while its therapeutic targeting through antibody-drug conjugates like Sacituzumab govitecan has shown clinical effectiveness, particularly in metastatic UC. However, heterogeneity in TROP2 expression, potential resistance mechanisms, and the significance of cytoplasmic vs. membranous localization remain areas of ongoing investigation. This review explores TROP2’s molecular characteristics, its role as a diagnostic and prognostic marker, and its implications as a therapeutic target in UC. By consolidating current evidence, we aim to provide insights into TROP2’s clinical relevance as a diagnostic and prognostic biomarker and its potential in personalized bladder cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.